Abstract
We appreciate Ismail Jatoi's interest in the TOSYMA study. He challenges the choice of the primary endpoints—the invasive breast cancer detection rates at screening and the following invasive interval cancer rates—as used in this randomised controlled trial comparing digital breast tomosynthesis plus synthesised two-dimensional mammography with digital mammography.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
